Drug Discovery

Iowa’s One Health Initiatives for Vaccine Development

In this GEN webinar, we will hear a series of presentations highlighting some of the high-quality bioscience research that is emerging from various industries across Iowa. Specifically, two of our presenters will discuss not only the manufacturing and testing capabilities to advance new vaccine candidates into clinical trials, but also some of the technological advances, facilities, and infrastructure that are being applied to pandemic preparedness and rapid vaccine development.

Vanquishing the Virus

In this on demand debut of “GEN Live”, Julianna LeMieux and Alex Philippidis discuss the latest medical advances in drug and vaccine development, as well as diagnostic and antibody testing. They go beyond the written word to share news and insights, ranking the frontrunner drug and vaccine candidates aiming to vanquish the virus. Attendees were able to ask questions live or via chat/social media.

Rapid Development of Multitagged Cell Lines for Drug Discovery

In this GEN webinar, sponsored by Tecan, we will discuss the development of the FAST-HDR vector system (patent pending)—a novel set of plasmids to be used in combination with CRISPR for the rapid development of multi-tagged cell lines for drug discovery. These plasmids allow the insertion of protein tags in genes of interest for downstream applications such as high-content imaging or luminescence detection on live cells. We will present examples of the use of these enhanced cellular models for high-throughput screening, target characterization, and live-cell microscopy.

Self-Amplifying mRNA Vaccines for Pandemic Rapid Response

In this GEN webinar, sponsored by TriLink Biotechnologies, we will hear about data innovations from seven years of research at Novartis Vaccines on self-amplifying mRNA technology and how this approach could enable the concept of vaccines on demand as a rapid response to a real threat rather that the deployment of strategic stockpiles based on epidemiological predictions of a possible threat.

The Secret to Improving the Therapeutic Index of Antibody Drug Conjugates

REGISTER NOW Broadcast Date: February 5, 2019Time: 8:00 am PT, 11:00 am ET, 17:00 CET Antibody-drug conjugates select ADCs) were initially developed to provide a selective targeting mechanism...

Cross-Functional Drug Discovery of Novel Non-Natural Entities

In this GEN webinar, sponsored by Dotmatics, we will highlight key features of an informatics solution that supports research of novel, non-natural drug entities such as bicyclic and stapled peptides, antibody- and peptide-drug conjugates, and non-natural RNAs.

Traveling through Space and Time: Trajectories of Our Most Powerful Immune...

Immune medicines, across cancers, infectious disease, and inflammatory disease, hold our closest promise to lasting curative therapies. In this sponsored webinar, IsoPlexis and various researchers will speak about the shift in space and time towards ‘Smaller’ to target our most powerful single cells, in order to accelerate timelines for finding these cures.

Exploring Novel Vaccine Characterization Methodologies

In this GEN webinar, we will discuss some typical workflows used to characterize the properties of vaccines, looking at properties such as particle size, surface charge, aggregation, and protein secondary structure.

COVID-19: Talking Next-Gen Diagnostics

Listen to the science writing talent from GEN in the second "GEN LIVE" interactive conversation on the latest science and medical news from the frontlines of the COVID-19 pandemic. In Episode 2 GEN editors Julianna LeMieux, Alex Philippidis and Kevin Davies will discuss the latest advances in COVID-19 diagnostics. This episode features Janice Chen, PhD, co-founder of Mammoth Biosciences and Jonathan Rothberg, PhD, CSO of 4Catalyzer.

Association Rate Constant: The Unsung Hero of Drug Discovery Kinetics

While the importance of ligand-receptor binding kinetics on drug action is becoming well established, focus to date has been almost entirely on the role of the dissociation constant on drug efficacy and duration of action. The association rate constant, in contrast, has been largely overlooked, with many investigators still considering it diffusion-limited and equivalent across a compound series. This GEN webinar aims to remedy that by turning the spotlight onto the undervalued and oft-ignored association rate constant.